Show Search Form

Search Results

type
answer	answer text answering member
tabling member	label

Search

1010153

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>This information is not available by local authority.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1012292

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The Government supports the principle that creators should be fairly rewarded for their work whilst ensuring that we continue to encourage investment in new content and innovative services. We are engaging with our European partners to achieve these aims during Trilogue negotiations on this Directive.</p> answering member 3980
	tabling member	1436 label Biography information for Paul Farrelly

1012293

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The Government has considered this issue in the context of its Brexit analysis. It has concluded that the reciprocal arrangements between UK Collective Management Organisations (CMOs) and EU CMOs to collect royalties from EU countries and distribute to creators in the UK are private commercial agreements which are expected to continue after the UK has exited the European Union.</p> answering member 3980
	tabling member	1436 label Biography information for Paul Farrelly

1012294

	type	WrittenParliamentaryQuestion
	answer	answer answer text The UK will always be a European country that advocates for cultural diversity as part of its global identity and is committed to continuing its contribution to and support of European culture. The Government has been clear that will be explore participation in any successor programme to Creative Europe. Where EU funding programmes are to the UK and EU's joint advantage, we want to discuss continued participation as part of the negotiations. Ultimately, the decision on which programmes are in the UK’s interests will be decided as part of the future partnership negotiations, which are ongoing. answering member 4115
	tabling member	1436 label Biography information for Paul Farrelly

1016320

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will ensure that access to medicines and medical devices continues, and patient safety is maintained, in both the United Kingdom and European Union markets.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be the UK competent authority during this period.</p><p> </p><p>For medical devices, CE marks are assigned by notified bodies (rather than competent authorities such as the MHRA), and during the implementation period UK notified bodies will continue to conduct third-party conformity assessment in the UK, and the results of these tests will continue to be used and recognised for both the UK and EU markets.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1020404

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p> </p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p> </p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.</p><p> </p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1020405

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as an EU competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p><strong></strong><br><br></p><p> </p> answering member 3977
	tabling member	1436 label Biography information for Paul Farrelly

1020408

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p> </p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p> </p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.</p><p> </p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1022956

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>Demand for children’s services is associated with a number of factors, including deprivation. The most deprived local authorities (LAs) have more looked after children (per 10,000 17 year olds), and these rates have grown faster than the least deprived LAs.</p><p>In preparation for the Spending Review, to help ensure decisions are based on the best available evidence, the government is working with the sector to develop a sharper and more granular picture of demand for children’s services.</p><p>We are also working with Ministry of Housing, Communities and Local Government as part of the Government’s Fair Funding Review of relative needs and resources, where new, up-to-date formulas are being developed to ensure funding distribution to councils is based on the best available evidence.</p><p>We welcome the contributions from the sector in this area, including Newton Europe’s Making Sense (2018) report and the Association of Directors of Children’s Services' continuing research reports, Safeguarding Pressures (2018).</p> answering member 4113
	tabling member	1436 label Biography information for Paul Farrelly

1024789

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>Public Health England (PHE) has run a number of ‘Be Clear on Cancer’ campaigns to help improve early detection of cancer including ovarian cancer. In 2014 PHE ran a pilot regional ovarian cancer campaign in the North West of England. In 2017, PHE ran a pilot campaign in the East and West Midlands which focussed on a range of abdominal symptoms, such as diarrhoea, bloating and discomfort that can be indicative of a number of cancers, including ovarian cancer. NHS England has invested over £200 million between 2017 and 2019, supporting Cancer Alliances to accelerate diagnosis and enhance quality of life.</p><p> </p><p>Staffordshire clinical commissioning groups commission diagnostic services for ovarian cancer fully in line with National Institute for Health and Care Excellence guidelines across the whole sustainability and transformation partnership.</p> answering member 4067
	tabling member	1436 label Biography information for Paul Farrelly